Alnylam Pharma's Pipeline Offers Plenty Upside Potential
While Alnylam Pharmaceuticals, Inc’s (NASDAQ: ALNY) proprietary RNA interference technology offers a powerful development platform, lead drugs patisiran and revusiran drive share value and the company also has a strong pipeline, Morgan Stanley’s David N Lebowitz said in a report. He initiated coverage of the company with an Overweight rating and a price target of $93.
Alnylam Pharma has ten 10 drugs in the pipeline and these focus on a wide range of indications from rare genetic diseases to more common disorders. “We see RNAi leading to a broad portfolio of approved drugs,” analyst David Lebowitz mentioned.
Alnylam Pharma has two lead drugs: Patisiran for the treatment of hereditary ATTR with polyneuropathy and Revusiran for hereditary ATTR with cardiomyopathy. These two drug candidates would “help validate the platform and derisk the earlier stage pipeline,” Lebowitz commented.
Plenty Upside Potential
The company’s pipeline offers “plenty of potential for upside,” the analyst stated. The pipeline includes:
- Fitusiran for hemophilia and other bleeding disorders
- ALNPCSsc for hypercholesterolemia
- ALN-AS1 for hepatic porphyrias
- ALN-GO1 for primary hyperoxaluria type 1
- ALN-AAT for alpha-1 antitrypsin deficiency
“The extensive pipeline sets up a crowded catalyst calendar, with frequent data releases. With Alnylam maintaining much of the economics across its pipeline, we see many opportunities for upside,” Lebowitz added.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email firstname.lastname@example.org with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Latest Ratings for ALNY
|Feb 2017||Ladenburg Thalmann||Initiates Coverage On||Buy|
|Oct 2016||Morgan Stanley||Downgrades||Overweight||Equal-weight|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.